| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
27,434 |
22,814 |
$1.08M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,344 |
17,997 |
$563K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,880 |
3,409 |
$253K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,228 |
4,686 |
$252K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
12,223 |
10,105 |
$184K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,820 |
4,934 |
$178K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,516 |
2,992 |
$59K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,251 |
2,957 |
$55K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
139 |
119 |
$44K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,276 |
1,058 |
$38K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,018 |
666 |
$25K |
| 93923 |
|
305 |
192 |
$23K |
| 95943 |
|
206 |
177 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,735 |
1,459 |
$17K |
| 95923 |
|
220 |
189 |
$11K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,108 |
873 |
$11K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,440 |
6,481 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
408 |
339 |
$8K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
223 |
199 |
$5K |
| 87428 |
|
216 |
208 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
66 |
64 |
$4K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
54 |
49 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
1,057 |
860 |
$2K |
| 93000 |
|
181 |
158 |
$2K |
| 99334 |
|
150 |
112 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
31 |
31 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
630 |
523 |
$1K |
| 99215 |
Prolong outpt/office vis |
23 |
18 |
$1K |
| 96160 |
|
471 |
419 |
$785.39 |
| 96127 |
|
260 |
217 |
$624.68 |
| 81002 |
|
1,440 |
1,306 |
$616.91 |
| 80305 |
|
91 |
73 |
$612.75 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
51 |
41 |
$315.38 |
| 99324 |
|
32 |
26 |
$271.29 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
178 |
135 |
$257.90 |
| 99401 |
|
15 |
13 |
$153.84 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
19 |
14 |
$5.22 |
| 81003 |
|
17 |
16 |
$2.10 |
| 3725F |
|
31 |
27 |
$0.00 |
| 99001 |
|
259 |
112 |
$0.00 |
| 99000 |
|
73 |
64 |
$0.00 |